[1]
Beird, H.C.; Bielack, S.S.; Flanagan, A.M.; Gill, J.; Heymann, D.; Janeway, K.A.; Livingston, J.A.; Roberts, R.D.; Strauss, S.J.; Gorlick, R. Osteosarcoma. Nat. Rev. Dis. Primers, 2022, 8(1), 77.
[2]
Ruiz-Fernandez de, Cordoba; Moreno, H; Valencia, K; Perurena, N; Ruedas, P; Walle, T; Pezonaga-Torres, A; Hinojosa, J; Guruceaga, E; Pineda, A; Abengozar-Muela, M; Cohonneau, D; Zandueta, C; Martinez-Canarias, S; Teijeira, A; Ajona, D; Ortiz-Espinosa, S; Moralles, X; Ortiz de Solorzano, C; Santisteban, M; Ramo, LI; Guembe, L; Strnad, V; Heymann, D; Hervas-Stubbs, S; Pio, R; Rodriguez-Ruiz, ME; de Andrea, CE; Vient, S; Melero, I; Lecanda, F; Martinez-Monge, R. Tumor ENPP1 (CD203a)/haptoglobin axis exploits myeloid-derived suppressor cells to promote post-radiotherapy local recurrence in breast cancer. Cancer Discov., 2022, 12, 1356-1377.
[3]
Cadé, M.; Munoz-Garcia, J.; Babuty, A.; Paré, L.; Cochonneau, D.; Fekir, K.; Chatelais, M.; Heymann, M.F.; Lokajczyk, A.; Boisson-Vidal, C.; Heymann, D. FVIII regulates the molecular profile of endothelial cells: functional impact on the blood barrier and macrophage behavior. Cell. Mol. Life Sci., 2022, 27(1), 102-116.
[4]
Grünewald, T.G.; Alonso, M.; Avnet, S.; Banito, A.; Burdach, S.; Cidre-Aranaz, F.; Di Pompo, G.; Distel, M.; Dorado-Garcia, H.; Garcia-Castro, J.; González-González, L.; Grigoriadis, A.E.; Kasan, M.; Koelsche, C.; Krumbholz, M.; Lecanda, F.; Lemma, S.; Longo, D.L.; Madrigal-Esquivel, C.; Morales-Molina, Á.; Musa, J.; Ohmura, S.; Ory, B.; Pereira-Silva, M.; Perut, F.; Rodriguez, R.; Seeling, C.; Al Shaaili, N.; Shaabani, S.; Shiavone, K.; Sinha, S.; Tomazou, E.M.; Trautmann, M.; Vela, M.; Versleijen-Jonkers, Y.M.; Visgauss, J.; Zalacain, M.; Schober, S.J.; Lissat, A.; English, W.R.; Baldini, N.; Heymann, D. Sarcoma treatment in the era of molecular medicine. EMBO Mol. Med., 2020, 12(11), e11131.
[5]
Taves, S.; Sun, J.; Livingston, E.W.; Chen, X.; Amiaud, J.; Brion, R.; Hannah, W.B.; Bateman, T.A.; Heymann, D.; Monahan, P. Hemophilia A and B mice, but not VWF-/- mice, diplay bone defects in congenital development and remodeling after injury. Sci. Rep., 2019, 9, 14428.
[6]
Brown, H.K.; Tellez-Gabriel, M.; PF, Cartron; Vallette, F.M.; Heymann, M.F.; Heymann, D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov. Today, 2019, 24(3), 763-772.
[7]
Chalopin, A.; Tellez-Gabriel, M.; Brown, H.K.; Vallette, F.; Heymann, M.F.; Gouin, F.; Heymann, D. Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy. J. Bone Oncol., 2018, 12, 83-90.
[8]
Tellez-Gabriel, M.; Charrier, C.; Brounais-Le Royer, B.; Mullard, M.; Brown, H.; Verrecchia, F.; Heymann, D. Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip. Eur. J. Cell Biol., 2017, 96, 110-118.
[9]
Ségaliny, A.I.; Mohamadi, A.; Dizier, B.; Lokajczyk, A.; Brion, R.; Lanel, R.; Amiaud, J.; Charrier, C.; Boisson-Vidal, C.; Heymann, D. Interleukin-34 promotes the tumour progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int. J. Cancer, 2015, 137, 73-85.
[10]
Télétchéa, S.; Stresing, V.; Hervouet, S.; Baud’huin, M.; Heymann, M.F.; Bertho, G.; Charrier, C.; Ando, K.; Heymann, D. Novel RANK antagonists for the treatment of bone resorptive disease: Theoretical predictions and experimental validation. J. Bone Miner. Res., 2014, 29, 1466-1477.
[11]
Chemel, M.; Le Goff, B.; Brion, R.; Cozic, C.; Berreur, M.; Amiaud, J.; Bougras, G.; Touchais, S.; Blanchard, F.; Heymann, M.F.; Berthelot, J.M.; Verrecchia, F.; Heymann, D. Interleukin-34 expression is associated with synovitis severity in rheumatoid arthritis. Ann. Rheum. Dis., 2012, 71, 150-154.
[12]
Moriceau, G.; Ory, B.; Mitrofan, L.; Riganti, C.; Blanchard, F.; Brion, R.; Charrier, C.; Battaglia, S.; Pilet, P.; Denis, M.G.; Shultz, L.D.; Mönkkönen, J.; Rédini, F.; Heymann, D. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res., 2010, 70, 10329-10339.
